KWANGDONG PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
KWANGDONG PHARMACEUTICAL CO.,LTD's Market Cap is ₩3167B. At end of 2025 it was ₩2918B. Ranked #637 of 2,421 in KR market (top 26%), #374 of 781 on KOSPI (top 48%), #67 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 29%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 316.73B KRW | KR#637/2,421 Sec#67/231 |
| Revenue | 1.71T KRW | KR#286/2,421 Sec#8/231 |
| Net Income | 22.94B KRW | KR#654/2,421 Sec#42/231 |
| Total Assets | 1.32T KRW | KR#403/2,421 Sec#19/231 |
| Net Assets | 711.80B KRW | KR#384/2,421 Sec#24/231 |
| Employees | 1,072 | KR#244/2,421 Sec#15/231 |
| Value | ||
| P/E | 13.81x | KR#1,001/2,421 Sec#55/231 |
| P/B | 0.45x | KR#678/2,421 Sec#28/231 |
| P/S | 0.19x | KR#322/2,421 Sec#3/231 |
| EV/EBITDA | 14.37x | KR#829/2,421 Sec#49/231 |
| FCF Yield | 18.04% | KR#354/2,421 Sec#7/231 |
| Profitability | ||
| ROE | 3.22% | KR#1,310/2,421 Sec#91/231 |
| ROA | 1.74% | KR#1,271/2,421 Sec#91/231 |
| Op. Margin | 1.96% | KR#1,386/2,421 Sec#97/231 |
| Revenue Growth | 5.50% | KR#1,166/2,421 Sec#114/231 |
| Earnings Growth | -16.34% | KR#909/2,421 Sec#57/231 |
| Financial Health | ||
| Debt Ratio | 85.49% | KR#1,419/2,421 Sec#163/231 |
| Total Debt | 306.19B KRW | KR#402/2,421 Sec#22/231 |
| FCF | 57.15B KRW | KR#273/2,421 Sec#15/231 |
| Cash | 140.99B KRW | KR#359/2,421 Sec#15/231 |
| Current Ratio | 1.34x | KR#1,334/2,421 Sec#140/231 |
| Net Debt/EBITDA | 4.93x | KR#1,022/2,421 Sec#76/231 |
| Dividend | ||
| Div. Yield | 1.63% | KR#966/2,421 Sec#52/231 |
| Div. Growth | 0.00% | KR—/2,421 Sec—/231 |
| Performance | ||
| 1Y Return | 4.95% | KR#644/2,421 Sec#40/231 |
| 1M Return | 3.92% | KR#840/2,421 Sec#60/231 |
| From 52W High | -50.31% | KR#1,408/2,421 Sec#108/231 |
| 1Y MDD | -52.44% | KR#1,095/2,421 Sec#91/231 |
| Trading | ||
| Volume | 120,793 shares | KR#695/2,421 Sec#62/231 |
| Trading Value | 781.6M KRW | KR#790/2,421 Sec#79/231 |
| Foreign Own. | 16.18% | KR#291/2,421 Sec#16/231 |
| Per Share | ||
| EPS | 461 KRW | KR#1,027/2,421 Sec#71/231 |
| BPS | 14,293 KRW | KR#728/2,421 Sec#50/231 |
Company Info
Kwangdong Pharmaceutical, established in 1963 and headquartered in Gwacheon-si, Gyeonggi-do, secured domestic consignment sales rights for Samdasoo until 2029 through a re-contract with Jeju Development Corporation in 2025. The company operates a Pharmacy Business Division for traditional medicines like Ssanghwatang and Woohwangchungsimwon, and an ETC Business Division for specialized pharmaceuticals such as the anti-cancer drug Lenara and vascular fortifier Venitol. Its F&B Sales Division markets beverages like Vita500, Corn Silk Tea, Hogaengnamu Tea, and Jeju Samdasoo, solidifying its brand power in the pharmaceutical and food sectors.